natgillin/translations-raw huggingface dataset:
Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).
profilaksu venske tromboembolije u bolesnika vezanih uz krevet zbog akutne bolesti uključujući akutno zatajenje srca, akutno zatjenje disanja, teške infekcije kao i pogoršanje reumatskih bolesti koja uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg / 0,4 ml)
Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).
profilaksu venske tromboembolije u bolesnika vezanih uz krevet zbog akutne bolesti uključujući akutno zatajenje srca, akutno zatjenje disanja, teške infekcije kao i pogoršanje reumatskih bolesti koje uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg/0,4 ml),
Prophylaxis of venous thromboembolism, especially in patients immobilised because of severe conditions, including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to 40 mg/0.4 mL strength)
Profilaksa venske tromboembolije osobito u bolesnika koji nisu mobilni zbog teških stanja uključujući akutno zatajenje srca, akutno zatjenje disanja, teške infekcije kao i pogoršanje reumatske bolesti koja uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg / 0,4 ml).
Prophylaxis of venous thromboembolism, especially in patients immobilised because of severe conditions, including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to 40 mg/0.4 mL strength)
Profilaksa venske tromboembolije, osobito u bolesnika koji nisu mobilni zbog teških stanj,a uključujući akutno zatajenje srca, akutno zatjenje disanja, teške infekcije kao i pogoršanje reumatske bolesti koja uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg / 0,4 ml).
Prophylaxis of venous thromboembolism, especially in patients immobilised because of severe conditions, including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to 40 mg/0.4 mL strength)
Profilaksa venske tromboembolije, osobito u bolesnika koji nisu mobilni zbog teških stanja uključujući akutno zatajenje srca, akutno respiratorno zatajenje, teške infekcije kao i pogoršanje reumatske bolesti koje uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg/0,4 ml).
Prophylaxis of venous thromboembolism, especially in patients immobilised because of severe conditions, including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to 40 mg/0.4 mL strength)
Profilaksa venske tromboembolije, osobito u bolesnika koji nisu mobilni zbog teških stanja, uključujući akutno zatajenje srca, akutno zatjenje disanja, teške infekcije kao i pogoršanje reumatske bolesti koja uzrokuje imobilnost bolesnika (odnosi se na jačinu od 40 mg/0,4 ml).
Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.
profilaksu venske tromboembolije, naročito u bolesnika koji se podvrgavaju ortopedskom, općekirurškom ili onkološkom kirurškom zahvatu,
Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.
profilaksu venske tromboembolije, naročito u bolesnika koji se podvrgavaju ortopedskom, općekirurškom ili onkološkom kirurškom zahvatu;
Prophylaxis of VTE - Patients with creatinine clearance <50 ml/min are at increased risk of bleeding and VTE and should be treated with caution (see sections 4.2, 4.3 and 5.2).
Profilaksa VTE - Bolesnici s klirensom kreatinina <50 ml/min imaju povećan rizik od krvarenja i treba ih liječiti uz oprez (vidjeti dio 4.2, 4.3 i 5.2).
Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol), or a suitable alternative such as a urate oxidate (e.g. rasburicase) starting 12-24 hours prior to the infusion of Gazyvaro as per standard practice (see section 4.2).
Profilaksa bi se trebala sastojati od odgovarajuće hidracije i primjene urikostatika (npr. alopurinola) ili neke druge prikladne terapije, poput urat oksidaze (npr. razburikaze), započevši 12 – 24 sata prije infuzije lijeka Gazyvaro u skladu s uobičajenom praksom (vidjeti dio 4.2).
Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol), or suitable alternative such as a urate oxidase (e.g. rasburicase) starting 12-24 hours prior to start of therapy as per standard practice.
Profilaksa bi se trebala sastojati od odgovarajuće hidracije i primjene urikostatika (npr. alopurinola) ili neke druge prikladne terapije, poput urat oksidaze (npr. razburikaze), započevši 12 do 24 sata prije početka terapije u skladu s uobičajenom praksom.
Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol), or suitable alternative treatment such as urate oxidase (e.g. rasburicase), starting 12-24 hours prior to start of Gazyvaro infusion as per standard practice (see section 4.4).
Profilaksa bi se trebala sastojati od odgovarajuće hidracije i primjene urikostatika (npr. alopurinola) ili neke druge prikladne terapije, poput urat oksidaze (npr. razburikaze), započevši 12 – 24 sata prije početka infuzije lijeka Gazyvaro u skladu s uobičajenom praksom (vidjeti dio 4.4).
Prophylaxis treatment
Profilaksa
Prophylaxis treatment
Profilaksa:
Prophylaxis with acetylsalicylic acid (and other anticoagulants in high risk patients) was mandatory for all patients in clinical studies.
Profilaksa acetilsalicilnom kiselinom (i drugim antikoagulansima u visokorizičnih bolesnika) bila je obavezna za sve bolesnike tijekom kliničkih ispitivanja.
Prophylaxis with acetylsalicylic acid (and other anticoagulants in high risk patients) was mandatory for all patients in clinical studies.
Profilaksa acetilsalicilnom kiselinom (i drugim antikoagulansima u visokorizičnih ispitanika) bila je obavezna za sve bolesnike tijekom kliničkih ispitivanja.
Prophylaxis with appropriate antihistamines prior to initiating therapy with efavirenz in children may be considered.
Može se razmotriti profilaktička primjena odgovarajućih antihistaminika prije početka liječenja djece efavirenzom.
Prophylaxis with appropriate antihistamines prior to initiating therapy with efavirenz in children may be considered. .
Može se razmotriti profilaksa odgovarajućim antihistaminicima prije početka liječenja djece efavirenzom.
Prophylaxis with appropriate antihistamines prior to initiating therapy with efavirenz in children may be considered..
Može se razmotriti profilaksa odgovarajućim antihistaminicima prije početka liječenja djece efavirenzom.
Proportion
Omjer
Proportion (%) (95% CI) 1
Udio (%) (95%CI)1
Proportion (%) of patients with HIV-1 RNA
Udio (%) bolesnika s
Proportion (%) of patients with HIV-1 RNA
Udio (%) bolesnika s HIV-1 RNK
Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by subgroup
Bolesnici zaraženi virusom HIV-1 kod kojih je virus suprimiran
Proportion (%) of patients with proven/probable Aspergillosis
Udio (%) bolesnika s dokazanom/vjerojatnom aspergilozom
Proportion (%) of patients with proven/probable IFIs
Udio (%) bolesnika s dokazanom/vjerojatnom IGI
Proportion (%) receiving laser rescue over 12 months
12 mjeseci podvrgnuti laseru
Proportion Achieving HbA1c <7%
Udio bolesnika koji su postigli HbA1c < 7
Proportion of Hgb Responders (%)
Udio bolesnika s odgovorom Hgb (%)
Proportion of patients
Udio bolesnika s
Proportion of patients achieving a clinically relevant improvement in HAQ-DI at week 24 (change from baseline of ≥ 0.3 units) was higher for tocilizumab subcutaneous every other week (58%) versus placebo (46.8%).
Udio bolesnika koji su nakon 24 tjedna postigli klinički značajno poboljšanje HAQ-DI rezultata (promjena za ≥ 0,3 jedinice u odnosu na početnu vrijednost) bio je veći u skupini liječenoj supkutanom formulacijom tocilizumaba jedanput svaka dva tjedna (58%) nego u bolesnika koji su primali placebo (46,8%).
Proportion of patients achieving HbA1c < 7 %
Udio bolesnika koji su postigli HbA1c < 7
Proportion of patients achieving reductions in HbA1c
Udio bolesnika koji su postigli smanjenje HbA1c
Proportion of patients achieving treatment response at Week 48 (confirmed ≥1 log10 copies/ml decrease in viral load compared to baseline), according to tipranavir baseline mutation score and enfuvirtide use in RESIST patients
Udio bolesnika s terapijskim odgovorom nakon 48. tjedna (potvrđeno smanjenje virusnog opterećenja ≥1 log10 kopija/ml u usporedbi s početkom), u odnosu na početni „,mutacijski skor“ i primjenu enfuvirtida u bolesnika u RESIST ispitivanjima
Proportion of patients receiving anthracycline and cyclophosphamide chemotherapy responding by treatment group and phase – cycle 1
Udio bolesnika koji su primali kemoterapiju antraciklinom i ciklofosfamidom u kojih je postignut odgovor, po terapijskoj skupini i fazi – 1. ciklus
Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase
Udio bolesnika koji su primali kemoterapiju cisplatinom u kojih je postignut odgovor, prema terapijskoj skupini i fazi
Proportion of patients who gained:
Udio bolesnika s povećanjem za:
Proportion of patients who met serum uric acid target (<6.0 mg/dL)
Udio bolesnika koji su postigli ciljnu razinu mokraćne kiseline u serumu (<6,0 mg/dl)
Proportion of patients with ACR responses in studies PALACE 1, PALACE 2 and PALACE 3 and pooled studies at Week 16
Udio bolesnika s odgovorima ACR u ispitivanjima PALACE 1, PALACE 2 i PALACE 3 te objedinjenim ispitivanjima u 16. tjednu
Proportion of patients with increased ALT activity in clinical studies
Udio bolesnika s povišenom aktivnošću ALT-a u kliničkim ispitivanjima
Proportion of patients with no radiographic
Udio bolesnika bez radiografskih promjena
Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dL (357 µmol/L) Last Three Monthly Visits
Udio bolesnika s razinama mokraćne kiseline u serumu <6,0 mg/dl (357 µmol/l) Zadnje tri mjesečne kontrole
Proportion of patients with SREs (%)
udio bolesnika s koštanim
Proportion of patients with SREs (%)
Udio bolesnika s koštanim događajem (%)
Proportion of patients with ≥ 15 letters improvement from baseline best corrected visual acuity in the study eye (pooled, ITT population)
Udio bolesnika s poboljšanjem od ≥ 15 slova u odnosu na početne vrijednosti najbolje korigirane oštrine vida (BCVA) u ispitivanom oku
Proportion of patients with ≥15 letters gain from baseline
Udio bolesnika s povećanjem od ≥ 15 slova od početne vrijednosti
Proportion of patients with ≥15 letters gain from baseline
Udio bolesnika s povećanjem od ≥15 slova od početne vrijednosti
Proportion of patients with ≥15 letters gain from Baseline (%)
Udio bolesnika s povećanjem od ≥15 slova od početne vrijednosti (%)
Proportion of patients with≥15 letters gain from baseline
Udio bolesnika s povećanjem od ≥15 slova od početne vrijednosti
Proportion of Randomized Patients in Remission at 12 Months and at 18 Months
Udio randomiziranih bolesnika u remisiji nakon 12 mjeseci i nakon 18 mjeseci
Proportion of Randomized Patients with Induction of Remission after 12 Months of Treatment
Udio randomiziranih bolesnika s induciranom remisijom nakon 12 mjeseci liječenja
Proportion of serum phosphorus responders at Week 12 (%)
Udio ispitanika u kojih je uočena promjena razine fosfora u serumu u 12. tjednu (%)
Proportion of subjects relapsed
Udio ispitanika s relapsom
Proportion of subjects that achieved
Udio ispitanika koji su postigli promjenu u razini Hb-a
Proportion of subjects that achieved normalised Hb at Week 12 (%)
Udio ispitanika koji su postigli normalnu razinu Hb-a u 12. tjednu (%)
Proportion of subjects with Scalp Psoriasis PGA (ScPGA) 0 or 1, n/N (%)b
Udio ispitanika s rezultatom psorijaze vlasišta (ScPGA) 0 ili 1 prema općoj procjeni liječnika, n/N (%)b
Proportion of Survival
Udjel preživljenja
Proportion of women with fracture (%)
Udio žena s frakturama (%)
Proportion of women with fracture (%)+
Udio žena s frakturom (%)+
Proportion relapsed
Udio u relapsu
PROPORTION RESPONDERS
UDIO BOLESNIKA S ODGOVOROM
Proportion undetectable (<300 copies/ml)b
Nemjerljivi udio (<300 kopija/ml)b
Proportion with 12 week confirmed disability progression*
Udio s potvrđenom progresijom onesposobljenosti u 12. tjednu
Proportion with 12-week confirmed disability progression
Udio progresije onesposobljenosti potvrđeno nakon 12 tjedna
Proportion with 24 week confirmed disability progression
Udio progresije onesposobljenosti potvrđeno nakon 24 tjedna
Proportion with 24-week confirmed disability progression*
Udio s potvrđenom progresijom onesposobljenosti u 24. tjednu
Proportion with 3-month Confirmed Disability Progression†
Udio bolesnika s napredovanjem onesposobljenosti potvrđenim nakon 3 mjeseca
Proportion with ferritin
Udio ispitanika s feritinom
Proportion with ferritin
Udio ispitanika s početnom vrijednosti feritina
Proportion with HIV-1 RNA < 400 copies/ml
Udio sa HIV-1 RNK < 400 kopija/ml
Proportiona in Mozobil and G-CSF (n=147b)
Udioa kod primjene lijeka Mozobil i G-CSF-a (n=147b)
Proportiona in Placebo and G-CSF (n=142b)
Udioa kod primjene placeba i G-CSF-a (n=142b)
Proportional increases of the plasma concentration were observed for doses from 2 – 60 mg.
Proporcionalno povišenje koncentracije u plazmi bilo je primijećeno kod doza od 2 mg do 60 mg.
Proportional increases of the plasma concentration were observed for doses from 2–60 mg.
Proporcionalno povišenje koncentracije u plazmi bilo je primijećeno kod doza od 2 mg do 60 mg.
Proportional increases of the serum concentration were observed for doses from 2-60 mg.
Proporcionalno povišenje koncentracije u serumu bilo je primijećeno kod doza od 2-60 mg.
Proportions of patients achieving HbA1c <7% targets (%)
Udio bolesnika koji su postigli ciljni HbA1c < 7% (%)
Proportions of Subjects in the Once Daily versus Twice Daily Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA <80 copies/ml: Subgroup Analysis by Formulation
Udio ispitanika s HIV-1 RNK u plazmi < 80 kopija/ml nakon randomizacije za primjenu abakavira + lamivudina jedanput na dan naspram dvaput na dan u ispitivanju ARROW: analiza podskupina prema formulaciji lijeka
Proportions with HIV-1 RNA < 50 copies/ml (50% versus 47%) and < 400 copies/ml (54% versus 57%) at week 48 were also similar in each group (ITT population).
U obje skupine (uključena populacija) bio je sličan i udio bolesnika s HIV-1 RNK < 50 kopija/ml (50% prema 47%,) te onih s < 400 kopija/ml (54% prema 57%) u 48 tjednu.
Proportions with HIV-1 RNA < 50 copies/ml (50% versus 47%) and < 400 copies/ml (54% versus 57%) were also similar in each group (ITT population).
U obje skupine (populacija s namjerom liječenja) bio je sličan i udio bolesnika s HIV-1 RNK < 50 kopija/ml (50% naspram 47%), te onih s < 400 kopija/ml (54% naspram 57%).
Proposed action:
Predložena akcija:
Propotion of Patients
Udio bolesnika
Propranolol crosses the blood-brain barrier and the placenta, and is distributed into breast milk.
Propranolol prelazi krvno-moždanu barijeru i posteljicu, te se distribuira u majčino mlijeko.
Propranolol is a substrate for the intestinal efflux transporter, P-glycoprotein (P-gp).
Propranolol je supstrat P-glikoprotein (P-gp), koji služi za izbacivanje tvari iz crijeva.
Propranolol is almost completely absorbed after oral administration.
Propranolol je nakon oralne primjene gotovo u potpunosti apsorbiran.
Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4- hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation.
Propranolol se metabolizira kroz tri osnovna puta: aromatična hidroksilacija (uglavnom 4- hidroksilacija), N-dealkilacija praćena daljnjom oksidacijom bočnih lanaca, i izravnom glukuronidacijom.
Propranolol passes through breast milk, mothers being treated with propranolol who breastfeed their infant should inform their health care professional.
Propranolol prolazi kroz majčino mlijeko, stoga majke koje se liječe propranololom, a koje doje djecu, moraju obavijestiti svog zdravstvenog djelatnika.
Propranolol to treat high blood pressure
Propranolol za liječenje visokog tlaka
Propranolol was rapidly absorbed, the maximum plasma concentration generally occurring 2 hours after administration with a corresponding mean value around 79 ng/mL whatever the infant age.
Propranolol je bio brzo apsorbiran, maksimalna koncentracija u plazmi obično se javljala 2 sata nakon primjene, uz odgovarajuću srednju vrijednost oko 79 ng/mL, bez obzira na dob dojenčeta.
propranolol, carvedilol, timolol (used in the treatment of high blood pressure ),
propranolol, karvedilol, timolol (koriste se u liječenju visokog krvnog tlaka),
propranolol, carvedilol, timolol (used in the treatment of high blood pressure),
propranolol, karvedilol, timolol (koriste se u liječenju visokog krvnog tlaka),
Propulsive
Propulzivi
Propyl gallate (E310)
Propil galat (E310)
Propyl parahydroxybenzoate 0.2 mg Clear, colourless solution for injection.
Propil parahidroksibenzoat 0,2 mg Bistra, bezbojna otopina za injekciju.
Propyl parahydroxybenzoate 0.2 mg For the full list of excipients, see section 6.1.
Propil parahidroksibenzoat 0,2 mg Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
Propylene carbonate Glycerol formal
Oleinska kiselina Propilen karbonat Glicerol formal
Propylene glycol
propilenglikol
Propylene Glycol (E1520)
Propilenglikol (E1520)
Propylene glycol Indigo carmine (E 132)
propilenglikol indigo karmin (E 132)
Propylene glycol monomethyl ether (Dowanol PM)
Propilen glikol monometil eter (Dowanol PM)
Propylene glycol Potassium hydroxide Black iron oxide (E172)
propilenglikol kalijev hidroksid željezov oksid, crni (E172)
Propylene glycol Sodium hydroxide Povidone K17 Titanium dioxide
Propilenglikol Natrijev hidroksid Povidon K17 Titanijev dioksid
Propylene glycol which may cause skin irritation.
propilenglikol koji može izazvati nadraženost kože.
propylene glycol: May cause skin irritation.
propilen glikol: Može uzrokovati nadraženost kože.
Propylparahydroxybenzoate may cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm (if the medicinal product is not correctly administered).
Propilparahidroksibenzoat može uzrokovati alergijske reakcije (možda odgođene), a iznimno bronhospazam (ako se lijek ne primjenjuje pravilno).
ProQuad - Powder in vial and solvent in pre-filled syringe with 1 unattached needle - Pack of 1, 10, 20
ProQuad – prašak u bočici i otapalo u napunjenoj štrcaljki s 1 nepričvršćenom iglom – pakiranja od 1, 10, 20
ProQuad - Powder in vial and solvent in pre-filled syringe with 2 unattached needles - Pack of 1, 10, 20
ProQuad – prašak u bočici i otapalo u napunjenoj štrcaljki s 2 nepričvršćene igle – pakiranja od 1, 10, 20
ProQuad - Powder in vial and solvent in pre-filled syringe with attached needle - Pack of 1, 10
ProQuad – prašak u bočici i otapalo u napunjenoj štrcaljki s pričvršćenom iglom – pakiranje od 1, 10
ProQuad - Powder in vial and solvent in pre-filled syringe without needle - Pack of 1, 10, 20
ProQuad – prašak u bočici i otapalo u napunjenoj štrcaljki bez igle – pakiranja od 1, 10, 20
ProQuad - Powder in vial and solvent in vial - Pack of 1, 10
ProQuad – prašak u bočici i otapalo u bočici – pakiranje od 1, 10
ProQuad can be given at the same time as other childhood vaccines such as Prevenar, and/or hepatitis A vaccine, or with vaccines containing diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, or hepatitis B. A different place for the injection will be used for each vaccine.
ProQuad se može dati u isto vrijeme s drugim cjepivima za djecu kao što su Prevenar i/ili cjepivo protiv hepatitisa A ili s drugim cjepivima protiv difterije, tetanusa, acelularnog pertusisa, tipa B Haemophilusa influenzae, poliomijelitisa (inaktivirano cjepivo) ili hepatitisa B. Svako od cjepiva mora se ubrizgati na različito mjesto.
ProQuad contains sorbitol
ProQuad sadrži sorbitol.
ProQuad may be administered from 9 months of age.
ProQuad se smije primijeniti u dobi od 9 mjeseci.
ProQuad powder and solvent for suspension for injection
ProQuad prašak i otapalo za suspenziju za injekciju
ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live)
ProQuad prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki Cjepivo protiv morbila, parotitisa, rubele i varičele, živo
ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live).
ProQuad prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki Cjepivo protiv morbila, parotitisa, rubele i varičele, živo.
ProQuad powder and solvent for suspension for injection Measles, mumps, rubella and varicella vaccine (live)
ProQuad prašak i otapalo za suspenziju za injekciju Cjepivo protiv morbila, parotitisa, rubele i varičele, živo
ProQuad should not be given to pregnant women .
ProQuad se ne smije davati trudnicama.
ProQuad with Solvent for reconstitution supplied in a Pre-filled syringe:
ProQuad s otapalom za rekonstituciju isporučen u napunjenoj štrcaljki:
ProQuad with Solvent for reconstitution supplied in a Vial:
ProQuad s otapalom za rekonstituciju isporučen u bočici:
Prostacyclin-like associated adverse reactions
Nuspojave koje nastaju zbog sličnosti s prostaciklinima
Prostate cancer is known to be androgen sensitive and responds to inhibition of androgen receptor signalling.
Poznato je da je karcinom prostate osjetljiv na androgene i odgovara na inhibiciju signalizacije putem androgenih receptora.
Prostate problems
imate tegobe s prostatom
Prostate problems
tegobe s prostatom
prostatic specific antigen increased
Povišena vrijednost specifičnog antigena prostate
prostatic specific antigen increased
povišenje vrijednosti PSA
Prosthetic heart valves
Proteze srčanih zalistaka
Prosthetic heart valves and moderate to severe mitral stenosis
Prostetički srčani zalisci i umjerena do teška mitralna stenoza
Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Umjetni srčani zalisci koji zahtijevaju liječenje antikoagulansom (vidjeti dio 5.1)
Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).
Umjetni srčani zalisci koji zahtijevaju liječenje antikoagulansom (vidjeti dio 5.1).
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of edoxaban.
Ne očekuje se da će protamin sulfat i vitamin K utjecati na antikoagulacijsko djelovanje edoksabana.
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.
Ne očekuje se da bi protamin-sulfat i vitamin K utjecali na antikoagulacijsku aktivnost rivaroksabana.
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.
Ne očekuje se da bi protamin-sulfat ni vitamin K utjecali na antikoagulacijsku aktivnost rivaroksabana.
Protamine sulfate Zinc oxide Glycerol
protamin-sulfat cinkov oksid glicerol
Protamine sulphate m-cresol [1.76 mg/ml]
protaminsulfat metakrezol [1,76 mg/ml]
Protamine sulphate m-cresol [2.20 mg/ml]
protaminsulfat metakrezol [2,20 mg/ml]
Protamine zinc recombinant human insulin is an insulin whose absorption and onset of action is delayed by the addition of protamine and zinc leading to crystal formation.
Rekombinantni ljudski protamin-cink inzulin je inzulin čija se apsorpcija i početak djelovanja odgađaju dodatkom protamina i cinka, što dovodi do stvaranja kristala.
Protaphane 100 international units/ml Suspension for injection
Protaphane 100 internacionalnih jedinica/ml Suspenzija za injekciju